Brokerages predict that NuCana plc (NASDAQ:NCNA) will announce earnings of ($0.24) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for NuCana’s earnings. The lowest EPS estimate is ($0.26) and the highest is ($0.19). NuCana also reported earnings of ($0.24) per share during the same quarter last year. The business is expected to announce its next earnings results on Wednesday, August 18th.
Zacks’ EPS averages are a mean average based on a survey of research firms that cover NuCana.
NuCana (NASDAQ:NCNA) last released its quarterly earnings results on Tuesday, May 18th. The company reported ($19.00) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($16.86) by ($2.14).
NASDAQ NCNA traded down $0.05 during midday trading on Thursday, hitting $2.44. The company had a trading volume of 2,107 shares, compared to its average volume of 440,010. NuCana has a twelve month low of $2.20 and a twelve month high of $7.83. The stock has a market cap of $118.32 million, a P/E ratio of -2.12 and a beta of 0.77. The business has a 50-day moving average of $2.83.
A number of large investors have recently made changes to their positions in NCNA. Sectoral Asset Management Inc boosted its holdings in NuCana by 48.6% in the first quarter. Sectoral Asset Management Inc now owns 1,114,801 shares of the company’s stock worth $5,563,000 after acquiring an additional 364,801 shares in the last quarter. Baillie Gifford & Co. raised its stake in shares of NuCana by 10.2% in the first quarter. Baillie Gifford & Co. now owns 3,659,030 shares of the company’s stock worth $18,259,000 after purchasing an additional 339,700 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of NuCana by 95.4% during the fourth quarter. Renaissance Technologies LLC now owns 424,462 shares of the company’s stock valued at $1,906,000 after acquiring an additional 207,220 shares during the last quarter. Henry James International Management Inc. purchased a new stake in shares of NuCana during the first quarter valued at approximately $355,000. Finally, Hilltop Holdings Inc. purchased a new stake in shares of NuCana during the first quarter valued at approximately $191,000. Institutional investors and hedge funds own 53.34% of the company’s stock.
NuCana Company Profile
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer.
Featured Article: Neutral Rating
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.